Uveal Melanoma: Patient Candidacy for Tebentafusp

Source: OncLive, August 2021

Richard D. Carvajal, MD: We have the 202 [IMCgp100-202] study, which was basically untreated patients, a clear survival advantage. We have the 102 [IMCgp100-102 study] trial, where it’s a single-arm trial, but overall survival looks good compared to historical controls. Who are the patients you’re going to treat, and are there any patients who are HLA [human leukocyte antigen] eligible who you might not treat with tebentafusp?

READ THE ORIGINAL FULL ARTICLE